Statement: Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.
Primary_evidence: Adverse Events 1:   Total: 0/77 (0.00%)   Neutropenia  [1]0/77 (0.00%)   Left ventricular dysfunction 0/77 (0.00%)   Cardiac ischemia 0/77 (0.00%)   Gastrointestinal pain 0/77 (0.00%)   Colitis 0/77 (0.00%)   Febrile neutropenia 0/77 (0.00%)   Pulmonary/upper respiratory infection 0/77 (0.00%)   Diverticulitis 0/77 (0.00%)   Motor neuropathy 0/77 (0.00%)   Endometrial mucosa thinkening 0/77 (0.00%) Adverse Events 2:   Total: 12/85 (14.12%)   Neutropenia  [1]1/85 (1.18%)   Left ventricular dysfunction 1/85 (1.18%)   Cardiac ischemia 2/85 (2.35%)   Gastrointestinal pain 1/85 (1.18%)   Colitis 1/85 (1.18%)   Febrile neutropenia 3/85 (3.53%)   Pulmonary/upper respiratory infection 1/85 (1.18%)   Diverticulitis 1/85 (1.18%)   Motor neuropathy 1/85 (1.18%)   Endometrial mucosa thinkening 1/85 (1.18%)